Nanoscope Therapeutics Bolsters Board with Addition of Ophthalmic Veteran as Strategic Adviser

Nanoscope Therapeutics has enlisted the expertise of Vicente Anido Jr., Ph.D. to help the company advance its goal of developing sight-restoring gene therapies for retinal degenerative diseases. Anido's appointment as a strategic adviser is expected to support Nanoscope's clinical and corporate strategies, especially as the company progresses towards the potential commercialization of MCO-010.

Dallas-based Nanoscope Therapeutics Inc. appointed Vicente Anido Jr., Ph.D., as a strategic adviser to its board and management.

Nanoscope is a clinical-stage biotechnology company that is focused on developing gene therapies for retinal degenerative diseases with the aim of restoring sight.

In a statement, Nanoscope CEO and co-founder Sulagna Bhattacharya expressed her enthusiasm over Anido’s appointment and the value that he brings to the company. “His deep experience and accomplishments in building and commercializing profitable ophthalmic companies will provide valuable guidance to support our clinical and corporate strategy,” she said.

Anido’s appointment is expected to help Nanoscope further its clinical and corporate strategies, particularly as the company advances its platform of optogenetic therapies for restoring vision in individuals with inherited retinal degenerative diseases, according to the company.

The path to commercialization

Anido brings with him a wealth of experience in the field of ophthalmology with more than three decades of experience as an ophthalmic leader. Nanoscope said he will assist in the company’s path toward the potential commercialization of MCO-010.

“Nanoscope’s Multi-Characteristic Opsin optogenetic monotherapy, MCO-010, is a novel approach to treat inherited retinal diseases and I am eager to help the company navigate through advanced clinical development and towards commercialization,” Anido said in a statement. “MCO-010 demonstrates a compelling clinical profile with meaningful market opportunities. I look forward to working with the team in developing a successful clinical and corporate strategy to bring this potential sight-restoring technology to patients.”

Most recently, Anido was CEO and chairman at Aerie Pharmaceuticals. Before that, Anido led several companies including a role as the CEP at ISTA Pharmaceuticals, which was sold to Bausch & Lomb for $500 million in 2012.

Anido holds a Ph.D. in pharmaceutical sciences from the University of Missouri, Kansas City, and masters and bachelor of science degrees in pharmacy from West Virginia University.

Developing sight-restoring therapies

Nanoscope Therapeutics said it is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists.

Its lead asset, MCO-010, is in RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa with top-line data expected in the first quarter of this year.

It also has fully enrolled a Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. It said that preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.

Get on the list.
Dallas Innovates, every day.

Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.

One quick signup, and you’re done.  

R E A D   N E X T

  • Reveles' new DCT management platform broadens access to clinical trials by enabling patients to participate—without leaving their homes. The technology includes enabling eConsent from existing and potential patients; online video and audio between patients and healthcare providers; direct data collection including real-time data, compliance, and status view featuring eSource, eDiaries, devices, wearables, questionnaires, and surveys; and telemedicine tools.

  • In this week's roundup of hires, promotions, and accolades in North Texas, you'll also find news from Firehouse, Enseo, Cambium Learning, D Magazine, Lear Investment Management, Spacee, Envy Gaming, 5Q, Stream Realty Partners, Nanoscope, Crossplane Capital, Improving, TimelyMD and more.

  • Comerica Assembles South Dallas Business Banking Team

    Dallas-based financial services giant Comerica Bank has named Trent Sampson, Jerry Collazo, and Adriana Najera to its newly formed South Dallas Business Banking Team that is led by Group Manager Derric Hicks. "As the leading bank for business, it is imperative that we raise expectations in all the communities where we live and serve," Comerica Bank Dallas Market President Amanda Mahaney said in a statement. "For many years, we have provided retail banking services and made community investments in the South Dallas community. Now, Derric and his team will focus on finding access to capital solutions for underserved entrepreneurs and…

  • Dallas-based Nanoscope Therapeutics is developing therapies that could restore sight in patients. The company also recently announced a new gene therapy manufacturing partnership.

  • Sylvia Trent-Adams has become the seventh president of The University of North Texas Health Science Center at Fort Worth and the first black woman to lead a health science center in Texas. Her appointment was made formal this week by the school's board of regents. Adams was selected by the regents as the sole finalist for the position on Aug. 19 after an eight-month national search. State law requires university governing boards to name finalists for a presidency at least 21 days before making a permanent appointment. “From the first time I set foot on the HSC campus in January…